Clinical Trial Search

Primary: Change From Baseline to 12-Week Endpoint in the Functional Magnetic Resonance Imaging (fMRI) Mean Blood Oxygenation-Level-Dependent (BOLD) Response in the Amygdalae…

Primary: Adjusted Geometric (Geo) Mean-Fold Change at End of Period 1 From Baseline in Measured Glomerular Filtration Rate (mGFR) — 0.91; 0.99 fold change

Primary: Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score) — -2.00; -5.34; -6.01; -5.06 units on a scale — p=<0.0001

Primary: Visibility of Rotation Mark (Clearly Visible, Slightly Visible Acceptable) — 42.9; 71.4; 78.6; 46.4 Percentage of assessments

Primary: Responders to Treatment, Assessed by Duplex Ultrasound — 9 participants

Primary: The Percentage of Subjects With an Average of ≥3 Spontaneous Complete Bowel Movements (SCBM) Per Week Over the 24 Week Treatment Period — 20.7; 25.1 percentage of…

Primary: Number of Participants With Adverse Events — 30 participants

Primary: Observational Gait Components: Observational Comparison of Gait Components for: Gait Robot-alone Condition, FES-alone Condition, and Combined Gait Robot and FES. — 0; 6…

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 8; 18; 16 participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Stopping All Study Drugs (SVR12) — 67; 67 percentage of participants

Primary: Number of Participants Achieving Seroprotection for Anti Hep-B After a Primary Series of Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ — 131; 130…

Primary: Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Scale — 12.8; 9.8 units on a scale

Primary: Quality of Recovery Scores Post Operative — 183; 159 units on scale 40 (low) - 200 (high)

Primary: Pain Rating Index — 12.3 units on a scale — p=.001

Primary: Combined Change in Systolic and Diastolic Blood Pressures From Baseline to Week 12. — -1.0; -1.9 mm Hg